Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter — Application to juvenile myoclonic epilepsy
暂无分享,去创建一个
Christer Halldin | Lars Farde | Ikuo Odano | Per Karlsson | Andrea Varrone | Carolina Ciumas | Ivanka Savic | Aurelija Jucaite | C. Halldin | L. Farde | A. Varrone | A. Jucaite | I. Savic | P. Karlsson | I. Odano | C. Ciumas
[1] J. Swanson,et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications , 2002, Synapse.
[2] I. Kanno,et al. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models , 2010, Annals of nuclear medicine.
[3] M. Bannon,et al. Valproate robustly increases Sp transcription factor‐mediated expression of the dopamine transporter gene within dopamine cells , 2007, The European journal of neuroscience.
[4] Christine DeLorenzo,et al. Modeling Considerations for In Vivo Quantification of the Dopamine Transporter using [11C]PE2I and Positron Emission Tomography , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] C. Halldin,et al. Pet study of [11C] β‐CIT binding to monoamine transporters in the monkey and human brain , 1994, Synapse.
[6] W H Theodore,et al. Effect of Valproate on Cerebral Metabolism and Blood Flow: An 18F‐2‐Deoxyglusose and 15O Water Positron Emission Tomography Study , 1996, Epilepsia.
[7] A. Gjedde,et al. Quantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of Ligands , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] D Guilloteau,et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. , 1997, Journal of medicinal chemistry.
[9] Sabine Rona,et al. Chronic High‐Frequency Deep Brain Stimulation of the STN/SNr for Progressive Myoclonic Epilepsy , 2007, Epilepsia.
[10] C. Halldin,et al. [11C] beta-CIT, a cocaine analogue. Preparation, autoradiography and preliminary PET investigations. , 1993, Nuclear medicine and biology.
[11] S. Hong,et al. CBF changes in drug naive juvenile myoclonic epilepsy patients , 2007, Journal of Neurology.
[12] C. Halldin,et al. Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] C. Kilts,et al. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. , 2000, Nuclear medicine and biology.
[14] L. Farde,et al. Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] D. Wong,et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428 , 1993, Synapse.
[16] C. Halldin,et al. Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter , 2006, Journal of Pharmacology and Experimental Therapeutics.
[17] Yuan-Hwa Chou,et al. [11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[18] D. Guilloteau,et al. Visualization of the Dopamine Transporter in the Human Brain Postmortem with the New Selective Ligand [125I]PE2I , 1999, NeuroImage.
[19] B. Gulyás,et al. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE‐PE2I, a new dopamine transporter PET radioligand , 2009, Synapse.
[20] J. Edinger,et al. Reversible parkinsonism and cognitive impairment with chronic valproate use , 1996, Neurology.
[21] A. Lammertsma,et al. Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.
[22] Roger N. Gunn,et al. Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET , 1998, NeuroImage.
[23] Yuan-Hwa Chou,et al. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. , 2003, European journal of nuclear medicine and molecular imaging.
[24] S. Amara,et al. Dynamic regulation of the dopamine transporter. , 2003, European journal of pharmacology.
[25] Christer Halldin,et al. Radioligand Disposition and Metabolism — Key Information in Early Drug Development , 1995 .
[26] T. Greitz,et al. Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. , 1981, Journal of computer assisted tomography.
[27] J J DiStefano,et al. Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. , 1984, The American journal of physiology.
[28] F. Fazio,et al. The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT , 2001, Neurological Sciences.
[29] Sylvain Houle,et al. Lower dopamine transporter binding potential in striatum during depression , 2001, Neuroreport.
[30] J. Seidel,et al. Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[31] A. Hill,et al. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .
[32] Sylvain Houle,et al. Positron Emission Tomography Quantification of [11C]-Harmine Binding to Monoamine Oxidase-A in the Human Brain , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[33] Carolina Ciumas,et al. The dopamine system in idiopathic generalized epilepsies: Identification of syndrome-related changes , 2010, NeuroImage.
[34] K. Gale,et al. Subcortical structures and pathways involved in convulsive seizure generation. , 1992, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.
[35] Martin McKee,et al. Environmental Profile of a Community's Health (EPOCH): An Instrument to Measure Environmental Determinants of Cardiovascular Health in Five Countries , 2010, PloS one.
[36] N. Volkow,et al. Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[37] C. Greer,et al. Mediation of myoclonic seizures by dopamine and clonic seizures by acetylcholine and GABA. , 1977, Life sciences.
[38] C. Halldin,et al. Molecular Imaging of the Dopamine Transporter , 2010, The Journal of Nuclear Medicine.
[39] G. Schwarz. Estimating the Dimension of a Model , 1978 .
[40] C. Deransart,et al. The control of seizures by the basal ganglia? A review of experimental data. , 2002, Epileptic disorders : international epilepsy journal with videotape.
[41] C. Halldin,et al. Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy , 2008, Neurology.
[42] T. Jiang,et al. Cerebellum Abnormalities in Idiopathic Generalized Epilepsy with Generalized Tonic-Clonic Seizures Revealed by Diffusion Tensor Imaging , 2010, PloS one.
[43] Christer Halldin,et al. [18F]Flumazenil binding to central benzodiazepine receptor studies by PET – Quantitative analysis and comparisons with [11C]flumazenil – , 2009, NeuroImage.
[44] D. Guilloteau,et al. Synthesis and Ligand Binding of Nortropane Derivatives: N‐Substituted 2β‐Carbomethoxy‐3β‐(4′‐iodophenyl)nortropane and N‐(3‐ Iodoprop‐(2E)‐enyl)‐2β‐carbomethoxy‐3β‐(3′,4′‐disubstituted phenyl)nortropane. New High‐Affinity and Selective Compounds for the Dopamine Transporter. , 1997 .
[45] Christer Halldin,et al. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity , 2005, Biological Psychiatry.
[46] D. Comar,et al. PET for drug development and evaluation , 1995 .
[47] Ivanka Savic,et al. Structural changes in patients with primary generalized tonic and clonic seizures , 2006, Neurology.
[48] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[49] C. Halldin,et al. Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[50] H. Akaike. A new look at the statistical model identification , 1974 .
[51] G. Sedvall,et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.
[52] Harumasa Takano,et al. Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. , 2009, Journal of psychiatric research.
[53] Christer Halldin,et al. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[54] Claude Comtat,et al. Assessment of 11C-PE2I Binding to the Neuronal Dopamine Transporter in Humans with the High-Spatial-Resolution PET Scanner HRRT , 2007, Journal of Nuclear Medicine.
[55] Merja Haaparanta,et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia , 2001, Schizophrenia Research.
[56] Christer Halldin,et al. Measurement of Striatal and Extrastriatal Dopamine Transporter Binding with High-Resolution PET and [11C]PE2I: Quantitative Modeling and Test—Retest Reproducibility , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[57] J. M. Ollinger,et al. Positron Emission Tomography , 2018, Handbook of Small Animal Imaging.
[58] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[59] K. Zilles,et al. Human brain atlas: For high‐resolution functional and anatomical mapping , 1994, Human brain mapping.
[60] I. Alafuzoff,et al. Loss of dopamine uptake sites labeled with [3H]GBR-12935 in Alzheimer's disease. , 1990, European neurology.
[61] Roger N. Gunn,et al. Tracer Kinetic Modelling of the 5-HT1A Receptor Ligand [carbonyl-11C]WAY-100635 , 1998, NeuroImage.
[62] A. Gjedde,et al. Dopamine transporter changes in neuropsychiatric disorders. , 1998, Advances in pharmacology.
[63] J S Fowler,et al. Kinetic Modeling of Receptor‐Ligand Binding Applied to Positron Emission Tomographic Studies with Neuroleptic Tracers , 1987, Journal of neurochemistry.
[64] Christer Halldin,et al. [11C]β‐CIT‐FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography , 1996 .